Portfolio

Next-generation immunotherapeutic modalities

Animal vaccine R&D company

Innovative life support medical devices

Novel base editor to push the limits of gene editing

Discovering and developing FIC/BIC therapeutics

Developing novel cancer immunotherapy

Fully integrated CDMO platform

Biological payload delivery technologies

Innovative Regenerative Medicine

Transformative exosome therapeutics

Proprietary biomarker platform to develop cancer drugs

Solving technical bottlenecks in tumor microenvironment

Targeting the cancer cell cycle with next generation CDK inhibitors

Fc-Based Designer Biologics (FBDB™) platform

Full range of CRO solutions and services

Focused on increasing longevity via early detection and intervention

Novel therapeutics for immunology-related diseases

Focused on cell therapy

Immuno-oncology based on G protein-coupled receptor (GPCR)-mediated immunosuppression

Large high-end esoteric testing service provider

Novel modalities for immune reconstitution

Gene therapy company focused on Parkinson’s disease

Identify and discover new novel targets for antibody therapeutics

Treatments for neurodegenerative diseases

Focused on intraoperative neural monitoring

Accessible wearable exoskeleton for gait assistance

Regulatory T cell therapies to manage immune tolerance

Next-generation universal cell therapy drug development

Next generation adaptive cell therapy (ACT)

Cutting-edge multi-omics platform developing liquid biopsy assays

Novel way to develop and continuously evolve (CAR-T) therapeutics

Major discovery engine for antibodies

Multi-asset cardiovascular franchise

Discovery and development of CNS therapeutics

Addressing significant unmet needs in ophthalmology